Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer
Miguel Martín, Alvaro Rodríguez-Lescure, Amparo Ruiz, Emilio Alba, Lourdes Calvo, Manuel Ruiz-Borrego, Blanca Munárriz, César A Rodríguez, Carmen Crespo, Enrique de Alava, José Antonio López García-Asenjo, María Dolores Guitián, Sergio Almenar, Jesús Fernando González-Palacios, Francisco Vera, José Palacios, Manuel Ramos, Jose Manuel Gracia Marco, Ana Lluch, Isabel Alvarez, Miguel Angel Seguí, José Ignacio Mayordomo, Antonio Antón, José Manuel Baena, Arrate Plazaola, Alfonso Modolell, Amadeu Pelegrí, Jose Ramón Mel, Enrique Aranda, Encarna Adrover, José Valero Alvarez, José Luis García Puche, Pedro Sánchez-Rovira, Sonia Gonzalez, José Manuel López-Vega, GEICAM 9906 Study Investigators, M Martín, J A López García-Asenjo, A Rodríguez-Lescure, A Ruiz, S Almenar, E Alba, Luis Vicioso, L Calvo, M Dolores Guitián, M Ruiz-Borrego, J Palacios, B Munárriz, F Vera, C A Rodríguez, C Crespo, J Fernando González-Palacios, M Ramos, Alberto de la Cruz, J M Gracia Marco, Jesús Martín Angulo, A Lluch, Jauma Ferrer, I Alvarez, Irune Ruiz, M A Seguí, Amparo Sáez, J I Mayordomo, Manuel Moros, A Antón, M José Ríos, J M Baena, M Jesús Palomo, A Plazaola, Ricardo Rezola, A Modolell, Pilar De las Heras, A Pelegrí, Francisco Riu, J R Mel, Jesús Alba, E Aranda, Elena Fuentes, E Adrover, Gloria Peiró, J V Alvarez, J L G Puche, José Aneiros, P Sánchez-Rovira, Cristóbal Cueva, Sonia Gonzalez, J M López-Vega, M Francisca Garijo, Miguel Martín, Alvaro Rodríguez-Lescure, Amparo Ruiz, Emilio Alba, Lourdes Calvo, Manuel Ruiz-Borrego, Blanca Munárriz, César A Rodríguez, Carmen Crespo, Enrique de Alava, José Antonio López García-Asenjo, María Dolores Guitián, Sergio Almenar, Jesús Fernando González-Palacios, Francisco Vera, José Palacios, Manuel Ramos, Jose Manuel Gracia Marco, Ana Lluch, Isabel Alvarez, Miguel Angel Seguí, José Ignacio Mayordomo, Antonio Antón, José Manuel Baena, Arrate Plazaola, Alfonso Modolell, Amadeu Pelegrí, Jose Ramón Mel, Enrique Aranda, Encarna Adrover, José Valero Alvarez, José Luis García Puche, Pedro Sánchez-Rovira, Sonia Gonzalez, José Manuel López-Vega, GEICAM 9906 Study Investigators, M Martín, J A López García-Asenjo, A Rodríguez-Lescure, A Ruiz, S Almenar, E Alba, Luis Vicioso, L Calvo, M Dolores Guitián, M Ruiz-Borrego, J Palacios, B Munárriz, F Vera, C A Rodríguez, C Crespo, J Fernando González-Palacios, M Ramos, Alberto de la Cruz, J M Gracia Marco, Jesús Martín Angulo, A Lluch, Jauma Ferrer, I Alvarez, Irune Ruiz, M A Seguí, Amparo Sáez, J I Mayordomo, Manuel Moros, A Antón, M José Ríos, J M Baena, M Jesús Palomo, A Plazaola, Ricardo Rezola, A Modolell, Pilar De las Heras, A Pelegrí, Francisco Riu, J R Mel, Jesús Alba, E Aranda, Elena Fuentes, E Adrover, Gloria Peiró, J V Alvarez, J L G Puche, José Aneiros, P Sánchez-Rovira, Cristóbal Cueva, Sonia Gonzalez, J M López-Vega, M Francisca Garijo
Abstract
Background: Taxanes are among the most active drugs for the treatment of metastatic breast cancer, and, as a consequence, they have also been studied in the adjuvant setting.
Methods: After breast cancer surgery, women with lymph node-positive disease were randomly assigned to treatment with fluorouracil, epirubicin, and cyclophosphamide (FEC) or with FEC followed by weekly paclitaxel (FEC-P). The primary endpoint of study-5-year disease-free survival (DFS)-was assessed by Kaplan-Meier analysis. Secondary endpoints included overall survival and analysis of the prognostic and predictive value of clinical and molecular (hormone receptors by immunohistochemistry and HER2 by fluorescence in situ hybridization) markers. Associations and interactions were assessed with a multivariable Cox proportional hazards model for DFS for the following covariates: age, menopausal status, tumor size, lymph node status, type of chemotherapy, tumor size, positive lymph nodes, HER2 status, and hormone receptor status. All statistical tests were two-sided.
Results: Among the 1246 eligible patients, estimated rates of DFS at 5 years were 78.5% in the FEC-P arm and 72.1% in the FEC arm (difference = 6.4%, 95% confidence interval [CI] = 1.6% to 11.2%; P = .006). FEC-P treatment was associated with a 23% reduction in the risk of relapse compared with FEC treatment (146 relapses in the 614 patients in the FEC-P arm vs 193 relapses in the 632 patients in the FEC arm, hazard ratio [HR] = 0.77, 95% CI = 0.62 to 0.95; P = .022) and a 22% reduction in the risk of death (73 and 95 deaths, respectively, HR = 0.78, 95% CI = 0.57 to 1.06; P = .110). Among the 928 patients for whom tumor samples were centrally analyzed, type of chemotherapy (FEC vs FEC-P) (P = .017), number of involved axillary lymph nodes (P < .001), tumor size (P = .020), hormone receptor status (P = .004), and HER2 status (P = .006) were all associated with DFS. We found no statistically significant interaction between HER2 status and paclitaxel treatment or between hormone receptor status and paclitaxel treatment.
Conclusions: Among patients with operable breast cancer, FEC-P treatment statistically significantly reduced the risk of relapse compared with FEC as adjuvant therapy.
Source: PubMed